Heyholder
‹ Activism Filings

PharmGen Science, Inc. Q3 operating profit KRW 0.9 billion, down 32.2% from a year earlier; sales KRW 44.6 billion

PharmGen Science, Inc.· Periodic Report

AI summary · Not investment advice

Pharmgen Science sold KRW 44.6 billion in Q3 and earned KRW 0.9 billion from its main business, down 32.2% from a year earlier and 48.2% from the previous quarter.

Operating profit · 3 months

KRW 931.8 million

Key facts

Revenue (3 months)
KRW 44.6 billion
Net income (3 months)
KRW -2.3 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 41.5 billion
Revenue (year to date)
KRW 135.6 billion
Operating profit (prior-year 3 months)
KRW 1.4 billion
Operating profit (year to date)
KRW 4.5 billion
Net income (prior-year 3 months)
KRW -2.3 billionNet loss
Net income (year to date)
KRW -16.9 billionNet loss

Commentary

AI commentary · Not investment advice

What happened

Pharmgen Science filed its quarterly report with standalone results for the third quarter of 2026. Sales for the latest 3 months were KRW 44.59 billion. That is 7.4% more than the same 3 months a year earlier (KRW 41.51 billion). It is 6.5% less than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was KRW 931.8 million. That is 32.2% less than a year earlier (KRW 1.37 billion). It is 48.2% less than the previous quarter.

What changes for shareholders

Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 2.34 billion. A year earlier, the same 3 months showed a loss of KRW 2.28 billion.

For the year so far (January 1 to September 30), sales were KRW 135.63 billion. Operating profit was KRW 4.50 billion. Net income was a loss of KRW 16.91 billion.

Comments

No comments yet

Comments from shareholders will appear here.